Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Day 75 is Key Threshold in FVIII Inhibitor Development

Key clinical point: For previously untreated patients with severe hemophilia A, the risk of developing FVIII inhibitors becomes marginal after 75 exposure days.

Major finding: Less than 1% of children with severe hemophilia A developed inhibitors after 75 exposure days.

Study details: A prospective cohort study of 1,038 previously untreated patients with severe hemophilia A, of whom 899 (87%) were followed until 75 exposure days.

Disclosures: No funding sources were reported. The authors reported no conflicts of interest.

Citation:

van den Berg HM et al. Blood. 2019 Jun 11. doi: 10.1182/blood.2019000658.